A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus

ClinicalTrials.gov ID: NCT00657189

Public ClinicalTrials.gov record NCT00657189. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2A , Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Doses of MEDI-545, A Fully Human Anti-Interferon-Alpha Monoclonal Antibody, In Subjects With Systemic Lupus Erythematosus

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to evaluate the safety and tolerability of multiple doses of MEDI-545 in subjects with moderately to severely active Lupus.

Study identification

NCT ID: NCT00657189
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: MedImmune LLC; Industry
Enrollment: 87 participants

Conditions and interventions

Conditions

Interventions

MEDI-545 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 2008 (Type not available)
Primary completion: May 2010 (Actual)
Completion: May 2010 (Actual)
Last update posted: Aug 9, 2016

2008 – 2010

United States locations

U.S. sites: 22
U.S. states: 15
U.S. cities: 22

Facility	City	State	ZIP	Site status
Research Site	Anniston	Alabama	36207	—
Research Site	Huntington Beach	California	92646	—
Research Site	Upland	California	91786	—
Research Site	Colorado Springs	Colorado	80910	—
Research Site	Farmington	Connecticut	06030-5353	—
Research Site	Clearwater	Florida	33765-2616	—
Research Site	Ocala	Florida	34474	—
Research Site	Atlanta	Georgia	30303	—
Research Site	Decatur	Georgia	30033	—
Research Site	Marrietta	Georgia	30060	—
Research Site	West Fayetteville	Georgia	30269	—
Research Site	Baltimore	Maryland	21205	—
Research Site	Lansing	Michigan	48910	—
Research Site	Brooklyn	New York	10003	—
Research Site	Charlotte	North Carolina	28210	—
Research Site	Cincinnati	Ohio	45219	—
Research Site	Oklahoma City	Oklahoma	73104	—
Research Site	Charleston	South Carolina	29406	—
Research Site	Columbia	South Carolina	29204	—
Research Site	Houston	Texas	77004	—
Research Site	Sugarland	Texas	77479	—
Research Site	Seattle	Washington	98111	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00657189, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 9, 2016 · Synced Oct 23, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00657189 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →